Eicosanoids in human heart failure : pilot study of plasma epoxyeicosatrienoic and dihydroxyeicosatrienoic acid levels

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083948" target="_blank" >RIV/00023001:_____/23:00083948 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/23:10458596 RIV/00064203:_____/23:10458596
Result on the web
<a href="https://www.archivesofmedicalscience.com/pdf-159313-88417?filename=Eicosanoids%20in%20human.pdf" target="_blank" >https://www.archivesofmedicalscience.com/pdf-159313-88417?filename=Eicosanoids%20in%20human.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5114/aoms/159313" target="_blank" >10.5114/aoms/159313</a>

Result language
angličtina
Original language name
Eicosanoids in human heart failure : pilot study of plasma epoxyeicosatrienoic and dihydroxyeicosatrienoic acid levels
Original language description
Introduction: The role of eicosanoids, metabolites of arachidonic acid with cardio-renal activity, remains unclear in human heart failure (HF). Methods: We enrolled 50 patients with HF to measure plasma 14,15-EET and 14,15-DHET levels using commercial ELISA kits and compared them with 25 age- and sex-matched controls. Results: Both of the measured eicosanoids were significantly higher in the HF group: 14,15- EET (91.3 +/- 25.7 ng/ml vs. 64.95 +/- 35.4 ng/ml) and 14,15-DHET (10.58 +/- 2.06 ng/ml vs. 9.07 +/- 1.60 ng/ml), p for both < 0.001. Conclusions: We found that peripheral plasma eicosanoid (14,15-EET, 14,15- DHET) levels are raised in patients with HF compared to age- and sex-matched controls.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)